DGAP-News: Siemens Healthineers AG
/ Key word(s): Share Buyback
Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052 Share buyback - 8th Interim Reporting In the time period from and including 18 January 2021 until and including 22 January 2021, a number of 131,964 shares of Siemens Healthineers AG were bought back within the framework of the share buyback of Siemens Healthineers AG; on 03 October 2020, Siemens Healthineers AG disclosed pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014 (MAR) and Art. 2 para. 1 of the Delegated Regulation (EU) No. 2016/1052 the start of the share buyback on 07 October 2020. Shares were bought back as follows:
The transactions are published in a detailed form on the website of Siemens Healthineers AG (www.corporate.siemens-healthineers.com/investor-relations). The total volume of shares which were bought back within the framework of the share buyback in the time period from and including 07 October 2020 until and including 22 January 2021 amounts to 3,487,877 shares. The purchase of the shares of Siemens Healthineers AG is carried out by a credit institution that has been commissioned by Siemens Healthineers AG; the shares are repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). Munich, 25 January 2021 Siemens Healthineers AG
25.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Siemens Healthineers AG |
Henkestr. 127 | |
91052 Erlangen | |
Germany | |
Phone: | +49 800 188 188 5 |
Fax: | +49 9131 844552 |
E-mail: | contact@healthcare.siemens.com |
Internet: | https://www.corporate.siemens-healthineers.com |
ISIN: | DE000SHL1006 |
WKN: | SHL100 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1163093 |
End of News | DGAP News Service |
|
1163093 25.01.2021
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.